Unknown PHASE3 INTERVENTIONAL 2-arm NCT02963129

Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT

Treatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis.

Sponsor: Hospital Italiano de Buenos Aires

Conditions Epistaxis Hereditary Hemorrhagic Telangiectasia

Interventions Mupirocin Placebo

Updated 7 times since 2017 Last updated: Nov 9, 2016 Started: Jun 30, 2017 Primary completion: Jun 30, 2017 Completion: Dec 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02963129, this PHASE3 trial focuses on Epistaxis and Hereditary Hemorrhagic Telangiectasia and remains ongoing. Sponsored by Hospital Italiano de Buenos Aires, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Dec 2018 — Jan 2021 [monthly]

Unknown Status PHASE3

Status: Not Yet Recruiting → Unknown Status

▶ Show 2 earlier versions

Jun 2018 — Dec 2018 [monthly]

Not Yet Recruiting PHASE3
Jan 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hospital Italiano de Buenos Aires

Data source: Hospital Italiano de Buenos Aires

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Buenos Aires, Argentina